MAPT antibody (Middle Region)

Catalog No. ABIN2783223

Product Details anti-MAPT Antibody

Target: MAPT (Microtubule-Associated Protein tau (MAPT))

Binding Specificity: Middle Region

Reactivity: Human, Rat, Mouse, Pig

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MAPT antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Sequence: RGAAPPGQKG QANATRIPAK TPPAPKTPPS SGEPPKSGDR SGYSSPGSPG

Predicted Reactivity: Human: 100%, Mouse: 86%, Pig: 79%, Rat: 86%

Characteristics: This is a rabbit polyclonal antibody against MAPT. It was validated on Western Blot using a cell lysate as a positive control.

Purification: Affinity Purified

Immunogen: The immunogen is a synthetic peptide directed towards the middle region of human MAPT

Application Details

Application Notes: Optimal working dilutions should be determined experimentally by the investigator.

Comment:

Antigen size: 441 AA

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Target Details for MAPT

Target: MAPT (Microtubule-Associated Protein tau (MAPT))

Alternative Name: MAPT (MAPT Products)

Background: MAPT is differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. The mutations in the gene have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
Alias Symbols: DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, TAU
Protein Interaction Partner: Ywhaz, Prkaca, STUB1, PHGK, SRC, PRKAR1A, GSK3B, FYN, DCTN1, CSNK1A1, CDK2, AKT1, ABL1, YWHAQ, SGK1, MARK2, MARCH7, TUBB3, TUBA1B, UBC, TUBA4A, MARK4, PEG10, MARK3, MARK1, MAPK13, MAPK11, MAPK8, mapk14, Mapk12, LIMS1, HSPA1A, PPP5C, PPP2R4, CAPN2, PKN1, H
Protein Size: 441

Molecular Weight: 46 kDa

Gene ID: 4137

NCBI Accession: NM_005910, NP_005901

Pathways: MAPK Signaling, Microtubule Dynamics, M Phase, Regulation of Cell Size